Login to Your Account



Pharma: Clinic Roundup


Monday, June 25, 2012
• Novo Nordisk A/S, of Bagsvaerd, Denmark, said its ultra-long-lasting insulin degludec significantly reduced the rate of hypoglycemia at night in adults with Type II diabetes, while obtaining equivalent improvement in glucose control compared with insulin glargine over a 52-week period.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription